For Physicians


Placeholder text (you can add a block title above)

For Physicians

OncoGenex is an emerging leader in next-generation cancer therapeutics. Our mission is to accelerate transformative therapies to improve the lives of people living with cancer and other serious diseases. The company has developed a broad pipeline of late-stage product candidates that block the production of specific proteins that promote treatment resistance in cancer. OncoGenex’ first-in-class, innovative therapies have the potential to redefine treatment outcomes in a variety of cancers.

Phase 3

Custirsen is a highly specific clusterin inhibitor designed to improve survival in patients with advanced cancer. Production of the protein clusterin is a fundamental cellular repair mechanism that tumor cells exploit to evade destruction by anti-cancer therapies. Clusterin is over produced in many tumor types and increased clusterin production is associated with faster rates of cancer progression, treatment resistance, and shorter survival duration in patients. Custirsen binds to clusterin mRNA to block the production of clusterin protein, altering the tumor dynamics by slowing tumor growth and inhibiting tumor resistance to partner treatments, so that the benefits of therapy, including survival, may be extended.

Custirsen has Fast Track designation by the U.S. Food and Drug Administration for metastatic castrate-resistant prostate cancer (CRPC) and non-small cell lung cancer (NSCLC).

As part of Phase 1 and Phase 2 clinical trials, custirsen was administered to 294 patients with various types of cancer. The majority of adverse events were mild. The most common adverse events associated with custirsen consisted of flu-like symptoms. The most common serious adverse events (SAE) associated with custirsen were febrile neutropenia, fever, pleural effusion, and dyspnea. Each SAE was observed in approximately 2%-4% of patients.


Phase 2

Apatorsen (OGX-427) is designed to inhibit production of heat shock protein 27 (Hsp27), an intracellular protein that is elevated in many types of cancer. By inhibiting Hsp27, apatorsen may disable cancer cells’ defenses and overcome treatment resistance. Both the potential single-agent activity and synergistic activity of apatorsen with cancer treatments may increase the overall benefit of existing therapies and augment the durability of treatment outcomes, which could lead to increased patient survival.


Phase 1
Phase 2
Phase 3


Prostate cancer

Combination with 2nd-line chemotherapy (AFFINITY)

Non-small cell lung cancer

Combination with 2nd-line chemotherapy (ENSPIRIT)


Bladder cancer


Combination with 1st-Line Chemo (metastatic) (Borealis-1™)

Combination with 2nd-Line Chemo (metastatic) (Borealis-2™)

Non-squamous non–small cell lung cancer

Combination with 1st-line chemotherapy (advanced) (Spruce™)

Squamous non–small cell lung cancer

Combination with 1st-line chemotherapy (advanced) (Spruce-2™)

Pancreatic cancer

Combination with 1st-line chemotherapy (metastatic) (Rainier™)

Prostate cancer

Combination with prednisone (pre-chemo)

Combination with abiraterone acetate (pre- or post-chemo) (Pacific™)


Solid tumors

Current as of January 2015.

External Link Pop Up Window

You are now exiting the OncoGenex Web site and entering a third party Web site.

OncoGenex does not review the information contained on the following Web site for content, accuracy or completeness. Use of and access to the information are subject to the terms, limitations and conditions set by the Web site producer. OncoGenex makes no claims about the accuracy or any other aspect of the information contained on this Web site, nor does OncoGenex necessarily endorse this Web site.

Stay on OncoGenex Continue